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Discovery of most autosomal recessive disease genes has involved analysis of large, 
often consanguineous, multiplex families or small cohorts of unrelated individuals 
with a well-defined clinical condition. Discovery of novel dominant causes of rare, 
genetically heterogenous developmental disorders has been revolutionized by 
exome analysis of large cohorts of phenotypically diverse parent-offspring trios 1,2. 
Here we analysed 4,125 families with diverse, rare, genetically heterogeneous 
developmental disorders and identified four novel autosomal recessive disorders. 
These four disorders were identified by integrating Mendelian filtering (identifying 
probands with rare biallelic putatively damaging variants in the same gene) with 
statistical assessments of (i) the likelihood of sampling the observed genotypes from 
the general population, and (ii) the phenotypic similarity of patients with the same 
recessive candidate gene. This new paradigm promises to catalyse discovery of novel 
recessive disorders, especially those with less consistent or nonspecific clinical 
presentations, and those caused predominantly by compound heterozygous 
genotypes. 
 
We previously noted an exome-wide excess of inherited loss-of-function (LOF) 
variants in 1,133 individuals with undiagnosed rare developmental disorders (DD)1 
but recessive DDs were typically only observed in a single family 3. This N=1 problem 
for recessive disorders has been well-recognised 4. We hypothesized that by 
increasing sample size we would observe recurrent instances of both known and 
novel recessive disorders. 
 
Here we describe an exome analysis of 4,125 mainly simplex families with severe 
DDs recruited through Clinical Genetics services in the UK and Ireland. Clinical 
phenotype was systematically recorded using the Human Phenotype Ontology (HPO) 
5,6 . 1,053 of these families had plausibly causative de novo mutations in known 
disease genes (Methods).  To identify candidate recessive genes in the remaining 
3,072 families all rare (minor allele frequency, MAF,  less than 1%) biallelic 
(homozygous or compound heterozygous) protein-altering variants were identified 
in each proband.  We observed 74 candidate recessive genes where at least one 
allele was predicted to be LOF in two or more families. 
 
For four previously weakly implicated (described in one or two families) recessive 
disorders caused by variants in: LARP7 4,7, LINS 4,8, PIGT 9,10, COL25A111  we identified 
additional families in whom the phenotypic similarity was sufficient for us to 
consider that the evidence supporting these new recessive disorders is now 
compelling (Supplementary Table 1).  Furthermore, we identified (DEPDC5) or 
confirmed (COL9A3 12) apparently recessive forms of dominant disorders. This 
phenomenon of rare recessive forms of dominant disorders has been described 
previously 13,14. 
 
To rigorously assess the evidence supporting each candidate recessive gene, we 
developed a statistical approach that integrates the probabilities of sampling the 
observed genotypes and phenotypes by chance (Methods, Figure 1).  
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We classified protein-altering variants (Methods, Supplementary Figure 1) into two 
groups of predicted functional consequences: LOF and ‘functional’ (i.e. protein-
altering but not likely LOF, e.g. missense). The probability of drawing N unrelated 
families with similar biallelic genotypes by chance from the general population, was 
estimated as the probability of sampling two rare alleles by chance N times from 
3,072 random draws using Hardy-Weinberg rules for estimating expected genotype 
frequencies from allele frequencies (Methods). We estimated this probability 
separately for two classes of recessive genotype: biallelic LOF and compound 
heterozygous LOF/functional. First we calculated the cumulative frequency of rare 
LOF and missense variants using the Exome Aggregation Consortium dataset. The 
gene-specific cumulative allele frequencies from the ExAC dataset (European, non-
Finnish, ancestry) were highly concordant with the frequencies from unaffected 
parents (of European ancestry) (Supplementary Figure 2), showing that the datasets 
are comparable. Our method corrects for gene-specific levels of autozygosity 
(Supplementary Figure 3) and takes account of population structure by matching 
each proband within the DDD cohort to one of four continental populations within 
the ExAC dataset (Methods). We demonstrated that our method is well-calibrated by 
showing that the number of biallelic rare synonymous genotypes observed in 
probands closely follows the null distribution (Supplementary Figure 4). 
 
We estimated the probability of sampling N probands from unrelated families with 
the observed clinical phenotypic similarity using the sum of the maximum 
Information Content (maxIC) among pairwise comparisons between probands’ HPO 
terms as a summary metric and compared to a null distribution of N probands 
sampled randomly from among the 4,295 probands studied here  (Methods). We 
demonstrated that this metric is informative by comparing probands sharing 
protein-altering de novo mutations in the same gene to permuted data in which the 
proband-gene relationship is scrambled (Supplementary Figure 5). 
 
We integrated the p values obtained from the genotypic and phenotypic 
assessments described above using Fisher’s method (Table 1, Supplementary Table 
2). In effect, these analyses are testing each and every gene in the genome we can 
annotate (N=17,370), under two models (biallelic LOF and LOF/functional compound 
heterozygote), and so we set a conservative threshold for genome-wide significance 
of 1.44e-6 (0.05/17,370/2). At this threshold, we identified two genes exceeding 
genome-wide significance, HACE1 and KIAA0586, neither of which had previously 
been implicated in Mendelian disease in humans. 
 
We identified eight individuals in six families with compound heterozygosity for two 
apparent LOF variants (N=7) or a LOF and missense variant (N=1) in KIAA0586 (Figure 
2). Five out of the six families had a suspected diagnosis of Joubert syndrome (MIM 
213300) with a typical molar tooth sign on brain MR images present in all but one of 
the affected individuals. Ataxia, hypotonia and Duane anomaly were reported 
features in several of the affected individuals (Supplementary Table 3).  
 
KIAA0586 encodes TALPID3, which is a centrosomal protein required for ciliogenesis 
and sonic hedgehog signaling 15. Other genes associated with Joubert syndrome are 
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similarly critical for cilia function 16 . Mouse homozygous for a null mutation in the 
gene encoding Talpid3 lack cilia and are embryonic lethal, dying during 
organogenesis with randomized left-right patterning; typical characteristics of a 
ciliopathy 17. All patients were compound heterozygous, sharing the same LOF 
variant, p.(Arg143Lysfs*4). This variant was observed at a MAF of 0.4% (383/96534) 
in ExAC, more frequent than the cumulative MAF of other LOF variants in KIAA0586. 
Therefore we hypothesise that homozygosity for this allele is likely embryonic lethal 
and that our patients are compound heterozygous for a null allele and a 
hypomorphic allele. 
 
We identified three individuals from three families with biallelic rare LOF variants in 
HACE1, and an additional family with a homozygous inframe deletion of a single 
codon in three affected siblings (Figure 3). These variants were associated with 
intellectual disability and significant abnormality in resting muscle tone; five of the 
six affected individuals had a combination of hypotonia, dystonia 
and spasticity.  Only one (281381) of the six affected individuals was ambulant 
(Supplementary Table 3).   Brain MR images show brain atrophy and variable 
hypoplasia of the corpus callosum (Figure 3) 
 
HACE1 encodes a HECT domain containing E3 ubiquitin ligase, expressed in brain. 
Notably other brain expressed HECT domain E3 ubiquitin ligases have also been 
associated with intellectual disability 18 .  HACE1 regulates Rac1, a small GTPase with 
diverse roles in signaling.  A homozygous knock-out mouse model of HACE1 has been 
described 19 which has almost complete pre-weaning lethality, of unknown 
mechanism. 
 
We also identified four genes (MMP21, PRMT7, CSTB and COL9A3) with suggestive 
initial evidence (p<1e-4) but not meeting genome-wide significance (Table 1), two of 
which were previously implicated recessive causes of DDs (CSTB and COL9A3).  We 
further evaluated MMP21 and PRMT7 with co-segregation studies, deeper clinical 
assessment and animal models, and found compelling evidence for recessive 
causation.   
 
We identified two individuals and one fetus from two families compound 
heterozygous for different LOF and missense variants in MMP21, which encodes a 
matrix metalloproteinase (Figure 4). Both affected individuals and the affected fetus 
presented with visceral heterotaxy (situs ambiguous; MIM 306955), including 
complex heart malformations. The missense mutations lie in close proximity in the 
conserved zinc-binding site, both predicted to have a major impact on enzymatic 
activity (Figure 4). Biallelic damaging variants in MMP21 have been identified in 
heterotaxy patients in an independent study (Chris Gordon pers comm). 
 
MMP21 has been suggested to function during embryogenesis, and as a matrix 
metalloproteinase, may modulate cell proliferation and migration through regulating 
extracellular matrix remodeling 20 . Two heterotaxy mutant mouse models, Miri and 
Koli, were recovered from a phenotype-based mutagenesis screen with pathogenic 
Mmp21 missense mutations in the zinc binding domain (Figure 4). Mutants exhibit 
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visceral heterotaxy with heart defects commonly associated with heterotaxy (Figure 
4).  While heterotaxy can arise from motile cilia defects, videomicroscopy of the 
embryonic node showed normal cilia motility (Supplementary Movie), suggesting 
Mmp21 acts downstream of motile cilia.  
 
We identified six affected individuals from three families with compound 
heterozygous LOF/LOF or LOF/functional variants in PRMT7. The associated clinical 
phenotype is a phenocopy of pseudohypoparathyroidism [PHP; MIM 103580, also 
known as Albright Hereditary Osteodystrophy, AHO]. Mild intellectual disability with 
obesity and symmetrical shortening of the digits and posterior metacarpals and 
metatarsals were observed, similar to the acrodysostosis seen in PHP (Figure 5). Two 
families shared the same variant at the last base of the first coding exon, which may 
induce aberrant splicing rather than a missense change (Arg32Thr). PRMT7 encodes 
an arginine methyltransferase with several histone substrates 21. Protein modeling 
indicates that all the observed missense variants are likely to be damaging (Figure 5, 
Supplementary Figure 6). Shortly after birth (at P10), PRMT7 knock-out mice display 
significantly reduced body size, reduced weight (-48%), and shortened 5th 
metatarsal (Supplementary Figure 7). These mice are subviable with only about 45% 
the expected number of Prmt7tm1a/tm1a pups found at P14. The surviving adult 
Prmt7tm1a/tm1a mice exhibit increased fat mass, reduced length and limb bone 
anomalies, concordant with the human phenotypes. In addition, reduced bone 
mineral content and density was observed in Prmt7tm1a/tm1a mice, and early onset 
osteoporosis is observed in AHO. All six affected individuals are female and notably 
the mouse model exhibits markedly sexually dimorphic phenotypes including bone 
mineral content, density and 5th metacarpal length changes only significant in 
females (Figure 5 and Supplementary Table 4). Moreover, a strong female bias has 
been observed in other AHO-like disorders22,23.  
 
Discovering rare autosomal recessive disorders is challenging, especially for 
genetically heterogeneous disorders in outbred populations with small families. Only 
a small fraction of the predicted >1,000 autosomal recessive intellectual disability 
disorders have yet been discovered 24. New strategies for discovering novel recessive 
disorders are required. We have proposed the combined use of large-scale 
ascertainment of small families with diverse clinical presentations, exome 
sequencing and integrated probabilistic analysis of genotypic enrichment and 
phenotypic similarity. Integrating genotype and phenotype matching increased 
power to detect novel recessive disorders while not overly penalizing discovery of 
new disorders that result in variable or nonspecific clinical presentations (e.g. 
HACE1). Most (10/19) of the families we described here with one of the six recessive 
disorders shown in Table 1 had a single affected child, nonetheless, these families 
were enriched for affected siblings compared to the entire cohort (p=6.3e-5, Poisson 
test), suggesting that including families with affected siblings within our cohort 
boosts power to detect recessive disorders.  
 
Our method for identifying novel recessive disorders requires systematic genotype 
and phenotype data on a known number of families, and cannot be applied when 
collating only partial genotypic or phenotypic data on selected families. Phenotypic 
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diversity among families is fundamental for estimating the significance of phenotypic 
similarity for a given candidate gene. The power of this approach is maximal when 
recording of phenotype terms is complete and consistent. For example, the 
statistical significance of phenotypic similarity for PRMT7 (Table 1) is based on the 
initial HPO terms associated with individual 270360, which did not include 
annotation of the hand anomalies (Figure 5).  Adding the HPO term ‘short 
metacarpal’ post-hoc increases the significance of the phenotypic similarity p value 
considerably from 1.49E-03 to 7.00E-05, and consequently the combined genotypic 
and phenotypic p value for PRMT7 becomes genome-wide significant (p=1.97E-07).  
Unbiased clinical re-evaluation of probands sharing the same candidate gene will 
likely remain valuable. 
 
Recruiting clinicians also recorded whether affected individuals were reminiscent of 
a recognized genetic syndrome, and for three of the recessive disorders described 
above, the same suspected syndrome was annotated recurrently (KIAA0586 – 
Joubert; COL9A3 – Stickler; PRMT7 – Albrights Hereditary Osteodystropy). The 
statistical significance (Methods) of shared syndrome annotation (KIAA0586 – 1e-5 ; 
COL9A3 – 4.2e-4; PRMT7 – 8.2e-4) was greater than for HPO phenotype similarity 
(Table 1), suggesting that computational phenotype analysis does not yet capture all 
of the ‘gestalt’ information utilized by experienced clinicians. 
 
Mouse mutants provided additional support for all four novel recessive disorders 
described above. In principle, similarity between HPO terms and mouse mutant 
phenotypes 25 could be incorporated into combinatorial genotypic and phenotypic 
significance testing 26. However, the current lack of consistent phenotyping data on 
all mouse mutants and the incomplete and biased gene coverage of mouse mutants 
could lead to significant biases. 
 
Comprehensive discovery of all autosomal recessive causes of DDs will require much 
larger datasets. Inevitably this will necessitate international collaboration and 
harmonizing of phenotypic data. The adoption of standard, interoperable phenotype 
ontologies, such as HPO, and, crucially, ensuring they are applied consistently, will be 
essential. 
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Tables 
 
Table 1 Integrated genotype-enrichment and phenotype-matching: genes with combined p-value less than 1e-4 
 
Gene # LOF/ 
LOFa 
#LOF/ 
Funcb 
P(geno)c P(pheno)d Combinede Evidence Additional evidence 
KIAA0586 6 1 1.42E-06 5.60E-04 1.75E-08 Genome-wide 
significant 
Co-segregation in two affected sibs 
Mouse and chick mutants with ciliary phenotypes 
HACE1 3 0 2.39E-08 1.11E-01 5.50E-08 Genome-wide 
significant 
Co-segregation in one affected sib 
Three affected sibs with homozygous inframe 
deletion 
Mouse mutant with early lethality phenotype 
PRMT7 1 2 1.45E-04 1.49E-03 3.53E-06 Suggestive Co-segregation in three affected sibs
Concordant mouse mutant with AHO-like phenotype 
CSTB 2 0 3.16E-05 1.76E-02 8.56E-06 Suggestive Previously implicated gene 
COL9A3 2 0 3.89E-05 4.08E-02 2.28E-05 Suggestive Previously implicated gene 
MMP21 0 2 2.05E-03 1.03E-03 2.97E-05 Suggestive Co-segregation with affected sib 
Two mouse mutants with heterotaxy 
 
a Number of families with biallelic LOF variants 
b Number of families compound heterozygous for LOF and functional variants 
c Binomial p value of sampling N families, minimum of LOF/LOF and LOF/functional tests 
d Phenotype matching p value assessed by permutation 
e Genotype and Phenotype p values combined using Fisher’s methods
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Figure legends  
 
Figure 1 Overview of analytical strategy 
 
Figure 2 Clinical and neuroradiological features associated with biallelic variants in 
KIAA0586 
A. Family structures, genotypes and phenotype key of the six families of the affected 
individuals with biallelic mutations in KIAA0586.  The DECIPHER ID is given above and 
to the left of the pedigree symbol for each affected individual recruited to the DDD 
study.    NT indicates an unaffected individual who has not been tested from the 
family mutations in KIAA0586.  Where available an anterio-posterior (AP) facial 
photographs and a transverse section from the brain MR is given below the family 
tree.  The white dashed box and white lines indicate the expanded region of the 
same image illustrating the “molar tooth” shape of the brainstem that is considered 
characteristic of Joubert syndrome in Families 1, 2, 4 and 5.  In family 6 the 
brainstem shape is atypical for Joubert syndrome.  The DECIPHER ID is indicated in 
all images. Informed consent was obtained to publish photographs. B. A cartoon 
depicting the protein domain structure of KIAA0586 (1533 
aa) encompassing TALPID3 chain (100-1,343; in blue), which includes a highly 
conserved Region (467 – 554 aa; in orange) required for centrosomal localization and 
two coiled-coil (182-232 & 467-501 aa; in yellow) domains. A red asterix (coding 
region variant) or dashed line (essential splice site) is used to indicate the position of 
each pathogenic mutations identified in the families above. 
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Figure 3 Clinical and neuroradiological features associated with biallelic variants in 
HACE1 
A. Family structures and genotypes of four families.  The DECIPHER ID is given for 
each recruited affected individual. NT indicates an individual who has not been 
tested from the family mutations in HACE1.  Where available an anterio-posterior 
(AP) facial photographs and a transverse section from the brain MR is given below 
the family tree. The elder sibling in Family 4 is also recruited to DDD but on 
recruitment was considered to have a different disorder from his brother, primary 
microcephaly. Where available photographs  of the face, hands and feet are 
presented.  Saggital and transverse sections from the brain MR is given below the 
family tree.  The saggital images show hypoplasia of the corpus callosum and the 
transverse images show an apparently reduced brain volume due to paucity of white 
matter.  Informed consent was obtained to publish photographs. 
B. Protein domain structure of HACE1 (909 aa) encompassing 6 Ankyrin repeats (in 
orange) and 1 HECT (E6AP-type E3 ubiquitin-protein ligase) domain (574 – 909 aa; in 
blue). A red asterix indicates the position of each pathogenic mutation. 
C. Prediction of mutation consequence on tertiary protein structure based on PDB 
IDs: 4bbn and 3tug. The HECT domain is highly conserved and all models share the 
same fold. The deletion of Leu 832 has significant effect on the fold of the protein. 
This mutation disrupts the helix by perturbing the hydrophobic core of the domain. 
This suggests that the mutated protein (ΔLeu832) is unlikely to have the same fold. 
 
 
 
Figure 4 Features associated with biallelic variants in MMP21/Mmp21 in humans 
and mice 
A. Pedigrees and genotypes of two families, with DECIPHER IDs. Photograph showing 
mild craniofacial dysmorphisms including hypoplasia of the malar region and 
supraorbital ridges and prominent lips. Informed consent was obtained to publish 
the photograph. 
B. Modeling of the effect of variants on the tertiary structure of MMP21, based on 
PDB IDs 1Y93 and 1FBL. Wildtype and mutated residues shown in cyan. The 
His283Tyr mutation severely reduces Zn2+ binding.  The Ile285Thr mutation causes 
loss of hydrophobicity and weaker interactions with neighbouring non-polar amino 
acids (green) and should cause movements of surrounding residues potentially 
leading to conformational shifts that affect Zn2+ binding. 
C. Protein structure (569aa) encompassing signal peptide (1-24 aa; in orange), 
propeptide (25- 144 aa; in grey) and matrix metalloproteinase-21 chain  (145 – 
569  aa; in blue)  that includes 4 Hemopexin repeats, with the positions of the 
human mutations shown above, and positions of ENU-induced mutations in mice 
shown below.  
D. Necropsy picture of a Miri mutant with dextrocardia with anterior positioning of 
the aorta (Ao), indicating transposition of the great arteries (TGA), right lung 
isomerism, inverted liver lobation (1-3), and dextrogastria (Stm). Confocal episcopic 
microscopy showed: Miri mutant exhibiting dextrocardia with TGA (E) and 
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atrioventricular septal defect (AVSD) (F), Koli mutant with double outlet right 
ventricle (G), Miri mutant with dextrocardia with TGA and hypoplastic right ventricle 
(H), mutant with anomalous right subclavian artery from pulmonary trunk (I), and 
mutant with duplicated inferior vena cava (IVC) draining into bilaterally symmetric 
right atria, indicating right atrial isomerism (J).  
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Figure 5 Features associated with biallelic variants in PRMT7/Prmt7 in humans and 
mice 
A. Pedigrees and genotypes of three families. The DECIPHER ID is given for each 
recruited affected individual.  The father in Family 3 had a cleft lip which is thought 
to be coincidental. AP facial photographs of the affected individuals are given below 
the pedigrees.  In Family 2 and 3 pictures of the foot show shortened posterior 
metatarsals.  In Family 3 a photo of the hand of an affected individual shows 
brachydactyly with short metacarpals. Informed consent was obtained to publish 
photographs.   
B. Protein domain structure of PRMT7 (692 aa) encompassing two active  S-
adenosylmethionine-dependent methyltransferases (SAM or AdoMet-MTase) PRMT-
type domains (14 – 345 aa; in blue & 358 – 684 aa; in orange). Red asterixes indicate 
the positions of pathogenic mutations. 
C. Data derived from mice homozygous for a targeted inactivation of Prmt7 (null;  
Prmt7tm1a/tm1a ).  DEXA scanning at 14 weeks of age indicates: female null mice have a 
reduced bone mineral content (top left graph), both male and female null mice have 
elevated fat mass (as a percentage of total body mass; top right graph) and reduced 
body length as determined by distance from nose to the base of the tail (bottom 
right graph). X-Ray images from 14 week old mice show that the length of the 5th 
metacarpal was reduced in female null mice only.  Box-and-whiskers plots show min-
mean-max values.  P-values presented are either global adjusted p-values for 
genotype, or (for sexual dimorphism) the p-value for the interaction between sex 
and genotype.  
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Online Methods 
Families 
4,295 patients with severe, undiagnosed, developmental disorders and their parents 
(4,125 families) were recruited and systematically phenotyped at 24 clinical genetics 
centres within the UK National Health Service and the Republic of Ireland. The study 
has UK Research Ethics Committee approval (10/H0305/83, granted by the 
Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). 
Families gave informed consent for participation and specific additional consent for 
publication of photographs was sought and given by a subset of families.  
 
Clinical data (growth measurements, family history, developmental milestones, etc.) 
are collected using a standard restricted-term questionnaire within DECIPHER, and 
detailed developmental phenotypes for the proband are entered using the Human 
Phenotype Ontology 5. 
Exome sequencing 
Genomic DNA (approximately 1 µg) was fragmented to an average size of 150 bp and 
subjected to DNA library creation using established Illumina paired-end protocols. 
Adapter-ligated libraries were amplified and indexed via PCR. A portion of each 
library was used to create an equimolar pool comprising 8 indexed libraries. Each 
pool was hybridised to SureSelect RNA baits (6541 samples with Agilent Human All 
Exon V3 Plus with custom ELID # C0338371, and 5903 samples with Agilent Human 
All Exon V5 Plus) with custom ELID # C0338371) and sequence targets were captured 
and amplified in accordance with manufacturer’s recommendations. Enriched 
libraries were subjected to 75 base paired-end sequencing (Illumina HiSeq) following 
manufacturer’s instructions. 
 
Mapping of the short read sequences  for each sequencing lanelet was carried out 
using the BWA (version 0.59) 27 backtrack algorithm with the GRCh37 1000 Genomes 
phase II reference (also known as hs37d5). PCR and optically duplicated reads were 
marked using Picard (version 1.98) MarkDuplicates. Lanelets were spatially filtered 
to account for bubble artifacts and quality controlled (passing thresholds on 
percentage of reads mapped; percentage of duplicate reads marked; various 
statistics measuring INDEL distribution against read cycle and an insert size overlap 
percentage). Lanelets were then merged into BAMs corresponding to sample’s 
libraries and duplicates were marked again with Picard after which they were then 
merged into BAMs for each sample. Finally sample level bam improvement was 
carried out using GATK (version 3.1.1) 28 and samtools (version 0.1.19) 29. This 
consisted of re-alignment of reads around known and discovered INDELs followed by 
base quality score recalibration (BQSR) both using the GATK, lastly samtools calmd 
was applied and indexes were created.  Known INDELs for realignment were taken 
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from Mills Devine and 1000G Gold set and the 1000G phase low coverage set both 
part of the Broad’s GATK resource bundle version 2.2.  Known variants for BQSR 
were taken from dbSNP 137 also part of the Broad’s resource bundle. Finally, SNV 
and INDELs were called using GATK HaplotypeCaller (version 3.2.2), this was run in 
multisample calling mode using the complete dataset. GATK Variant Quality Score 
Recalibration (VQSR) was then computed on the whole dataset and applied to the 
individual sample variant calling format (VCF) files.  
Annotation of functional consequence 
Minor Allele Frequency  
To define the rarity of each SNV and INDEL, the VCF is annotated with minor allele 
frequency (MAF) data from a variety of different sources. The MAF annotations used 
include data from 4 different populations of the 1000 Genomes project 30 [AMR, 
ASN, AFR & EUR], the UK10K cohort, the NHLBI GO Exome Sequencing Project (ESP) 
and an internal DDD allele frequency generated using unaffected parents. For allele 
matching of SNVs we use an exact match based on a key generated from four values 
(chromosome, position, reference allele and alternative allele). For allele matching 
of INDELS we use a less stringent approach where the key is constructed using a 
different four values (chromosome, position, slice and direction). This key requires 
both INDELs to be at the same locus (chromosome and position) while the slice is 
computed based on the DNA sequence difference between the reference and 
alternative alleles and direction is either deletion or insertion. 
Variant Effect Predictor 
To define the functional consequence of each variant (SNVs, INDELs and CNVs) 
annotations from the Ensembl variant effect predictor (VEP) 31 based on Ensembl 
gene build 76 are added to the VCF file. VEP produces a number of annotations 
including, SIFT and Polyphen predictions, ensembl transcripts, HGNC gene names 
and a prediction of the functional consequence for each variant. The transcript with 
the most severe consequence is selected and all associated VEP annotations are 
based on the effect that the variant has on that particular transcript. 
 
We categorised variants into two classes of variation from the VEP consequence 
predictions: 
● Loss of function (LoF): transcript_ablation, splice_donor_variant, 
splice_acceptor_variant, stop_gained, frameshift_variant 
● Functional: stop_lost, initiator_codon_variant, transcript_amplification, 
inframe_insertion, inframe_deletion, missense_variant, 
coding_sequence_variant 
 
In addition to the standard VEP-predicted consequences, we expanded the definition 
of splice donor variants to include those at the neighbouring last base of coding 
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exons, if it is guanine in the reference sequence, as these are highly conserved within 
the position weight matrix of splice donor sites 32 and exhibits a skew towards rare 
variants – a characteristic signature of functional impact – that in unaffected DDD 
parents is more akin to canonical splice donor sites than missense variants 
(Supplementary Figure 1). We identified bases in the human genome at the 3’ end of 
exons, where the base at that site was a guanine (specific to the strand of the 
transcript). Exon coordinates were obtained from GENCODE release 19 33, and 
sequence at these positions were extracted from the hs37d5 reference assembly 30. 
We only included sites which overlapped synonymous or missense variants to 
exclude sites outside of the coding sequence.  
Mendelian filtering 
Of the 4,125 families recruited to the DDD study, we excluded 1,053 families from 
downstream recessive analyses on the basis of having de novo mutations predicted 
to alter the coding sequence of genes already robustly linked to dominant or X-
linked developmental disorders. For the remaining families, we identified rare 
(maximum minor allele frequency less than 1%), protein-altering variants in the 
probands that were consistent with a recessive mode of inheritance. The remaining 
variants were either compound heterozygous variants or homozygous non-reference 
variants, averaging 3.2 variants per proband.  
 
The numbers of probands in each of the functional categories (biallelic LoF, or 
compound heterozygous LoF/functional) were tallied for each gene. For families with 
affected siblings found to share rare recessive genetic variants within a gene, only 
the eldest sibling was included in the tally, in order to have counts from independent 
families. 
 
The variant filtering was conducted in python, this analysis used version 0.2.0. 
Statistical genotypic assessment 
We tested all genes (coordinates from GENCODE release 19) for enrichment of rare 
(minor allele frequency < 1%), recessive LoF and functional (see above) genotypes in 
unrelated families. Because allele frequency can vary by population, and this affects 
the probability of randomly observing recessive genotypes, we calculated the 
cumulative frequency of rare alleles in each gene from the ExAC dataset version 0.3 
(accessed 2015-02) in four ancestral populations: European (excluding Finns) - NFE; 
African - AFR; East Asian - EAS and South Asian - SAS. Different alternate alleles at 
multiallelic sites were examined separately, using the most severe consequence 
relating to each allele. We classified each undiagnosed DDD proband into one of 
these four ancestral populations by projecting them onto a principal component 
analysis of 1000 Genomes populations (using SNPRelate): AFR (N=109), EAS (N=15), 
NFE (N=2799) and SAS (N=297).  
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Because rare recessive genotypes are much more likely to be observed in 
autozygous segments (inheriting DNA from a recent common ancestor from both 
parents, e.g. in the case of consanguinity), we used bcftools roh (version 1.0) to call 
autozygous segments across the entire exome, and determined the number of 
probands autozygous across each gene of interest. We then adjusted the probability 
of sampling two rare LoF alleles for the number of probands autozygous across each 
gene.  
 
The probability of drawing N unrelated families with recessive genotypes in the same 
gene by chance was estimated as the binomial probability (including autozygosity) of 
sampling two rare alleles of a specified functional category N or more times from 
random draws matched to our ancestral populations (i.e. 109 AFR, 15 EAS, 2799 NFE, 
297 SAS). We determined the entire set of combinations by which N or more families 
could be distributed across the four ancestral populations, and the probability of 
observing each combination using population-specific frequencies. We summed 
these probabilities across all possible combinations to obtain an aggregate 
probability for sampling N or more families by chance. 
 
An R package was developed to perform these statistical analyses, this analysis used 
version 0.5.0. 
Statistical phenotypic assessment 
HPO phenotype similarity 
Clinical geneticists referring each proband into the DDD study systematically 
recorded phenotypes using the Human Phenotype Ontology (HPO) 5. These terms 
were used to assess the probability that probands sharing the same candidate 
recessive share more similar clinical phenotypes than expected by chance. Similarity 
testing used the Human Phenotype Ontology version 2013-11-30. 
 
The similarity of HPO terms between two individuals was estimated as the maximum 
information content (maxIC) from pairwise comparisons of the HPO terms for the 
two individuals. For each pairwise comparison of two HPO terms we determined the 
information content for the most informative common ancestor of the two terms. 
The information content is calculated as the negative logarithm of the probability of 
the terms’ usage (or any of its descendant terms) within the population of all 4,295 
probands in the DDD study. 
 
The summary phenotype similarity score for a set of N probands was estimated as 
the sum of all the pairwise maxIC scores. The null distribution of this summary 
phenotype similarity score was simulated by randomly sampling sets of N probands 
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and calculating summary scores as above. The p-value was calculated as the 
proportion of simulated scores greater than or equal to the observed score. 
 
We demonstrated that this summary phenotype similarity score is both informative 
and well-calibrated by comparing probands sharing protein-altering de novo 
mutations in the same gene to permuted data in which the proband-gene 
relationship is scrambled (Supplementary Figure 5). The permuted data closely 
follows the expected null distribution. 
 
These analyses were conducted in Python, this analysis used version 0.3.1. 
Suspected syndrome similarity 
In addition to HPO annotation, recruiting clinicians also annotated whether affected 
individuals were reminiscent of a recognized phenotypically-defined syndrome. 
These suspected syndrome annotations were initially standardised to correct, for 
example, misspellings and abbreviated syndrome names.  
 
The similarity of suspected syndrome terms between two probands was calculated 
as the negative logarithm of the observed probability of selecting the rarest matched 
syndrome term between the probands. The observed probability of selecting each 
term was calculated as the frequency with which the term was used in the probands 
with at least one suspected syndrome. We compared the similarity of the probands 
for each candidate recessive gene to a null distribution constructed by simulating 
100000 permutations of randomly sampling probands from the set of probands with 
at least one suspected syndrome. 
Combining genotype-phenotype assessment p values 
For each gene, we integrated the p-values obtained from the genotypic and 
phenotypic assessments described above using Fisher’s method. For the genotypic 
tests, we had performed tests for two models (biallelic LoF and LoF/functional 
compound heterozygote). We selected the more significant genotypic test for each 
gene, since some genes had only biallelic LoF probands, while other genes only had 
LoF/missense compound heterozygotes. These analyses effectively are testing each 
and every gene in the genome, under the two models, and so we set a conservative 
threshold for declaring genome-wide significance of 1.44 x 10-6 (0.05/(17,370*2)). 
 
Code availability 
Software for variant filtering analyses available at:  
https://github.com/jeremymcrae/clinical-filter, this analysis used version 0.2.0. 
Software for HPO phenotype similarity analyses available at: 
https://github.com/jeremymcrae/hpo_similarity, this analysis used version 0.3.1. 
Software for recessive genotype enrichment analyses available at: 
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https://github.com/jeremymcrae/recessiveStats, this analysis used version 0.5.0. 
 
Protein modeling 
Identification of template protein structures 
Protein structures having high sequence homology with the protein to be modelled 
found by using the sequence similarity search tool at the Protein Data Bank in 
Europe. Where no hits with a high sequence homology were found, only the relevant 
domains were used for searching and the sequences of the matches recorded. For 
modeling PRMT7, a mouse structure with high sequence identity was found for the 
whole sequence (PDB ID: 4C4A). For MMP21 and HACE1 HECT domain, multiple 
template sequences were selected for modeling since the sequence identity was 
borderline for modeling (~30-40%).  
 
Structure Modeling 
The Swiss-Model server was used to model the protein structure based on sequence 
templates chosen in the previous step. The models were downloaded and where 
multiple template sequence were used, these were superposed using PDBeFold 
service so as to be on the same coordinate reference for comparison. If the fold of 
the multiple models were the same, only the model with highest sequence 
homology was used for further analysis (MMP21: Model built on PDB ID: 1y93; 
HACE1 HECT Domain: 3tug). Models were built for both the mutated and non-
mutated sequence for comparison and validation in the next step. 
 
Mutation Modeling 
Mutations were introduced in the modelling programme Chimera 34  and the best 
rotamer for the new amino acid based on inspection of conformational space around 
the mutation. The overall structure was optimised using the energy minimize 
function in Chimera with 100 cycles of steepest descent and 100 cycles of conjugate 
gradient energy minimisation. The energy minimised models of the mutated 
structures were compared with the models built for the mutated sequence in the 
previous step to validate the modelling strategy. 
 
Model Assessment 
Model assessments were done by comparison of the non-mutated and mutated 
structures in PyMol ( The PyMOL Molecular Graphics System, Version 1.7.4 
Schrödinger, LLC.). All figures of the structure models were also made using PyMol 
 
Mouse modeling of Mmp21 
Mouse Mutagenesis Screen and Recovery of Mmp21 Mutants 
Miri (B2b873) and Koli (b2b2458) mutant lines were recovered from a large-scale 
recessive mouse N-ethyl-N-nitrosourea mutagenesis screen conducted in C57BL6/J 
mice. Fetal echocardiography was used to identify mutants with congenital heart 
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disease (CHD)35,36 . Fetuses diagnosed with congenital heart defects were further 
analyzed by necropsy and imaging using micro computed tomography and/or 
episcopic confocal microscopy was conducted for detailed histopathological 
examination of intracardiac anatomy for CHD diagnosis37. This study was approved 
by the Institutional Animal Care and Use Committee of the University of Pittsburgh 
and conforms to NIH guidelines.  
 
Whole Exome Sequencing and Mutation Recovery of Mmp21 Mutations  
Genomic DNA from a Miri and Koli mutant were analyzed by whole mouse exome 
sequencing analysis using Agilent SureSelect Mouse All Exon Kit V1, followed by 
Illumina HiSeq 2000 sequencing to achieve a minimum of 50X average target 
sequence coverage (conducted by BGI Americas). Sequence reads were aligned to 
the C57BL6 reference genome (mm9) and analysis was carried out using CLCBio 
Genomic Workbench and GATK software. All variants were annotated with annovar 
and filtered against dbSNP128 and in-house mouse exome databases with custom 
scripts.  Homozygous coding variants recovered from each mutant line were 
genotyped across all mutants, with the pathogenic mutation identified as the single 
mutation consistently homozygous in all mutants. Thus the Miri line was shown to 
harbor a Mmp21 W177L pathogenic mutation, while Mmp21 Y325N pathogenic 
mutation was identified in the Koli mutant line. Further breeding of both lines across 
multiple generations has confirmed the Mmp21W177L and Mmp21Y325N mutations as 
the pathogenic mutations causing heterotaxy and complex CHD in the Miri and Koli 
mutant lines, respectively.  
 
Nodal Cilia Videomicroscopy 
The embryonic node from E7.75 embryos was dissected for analysis of cilia motility 
with 0.35µm microspheres (Polysciences) added to assess flow. Imaging was 
conducted using a Leica DMIRE2 inverted microscope equipped with a 100x oil 
objective and differential interference contrast optics. High-speed videos were 
collected at 200 fps using a Phantom v4.2 camera (Vision Research).  
 
Mouse modeling of Prmt7 
Mice homozygous for the Prmt7tm1a(EUCOMM)Wtsi allele (hereafter referred to as 
Prmt7tm1a/tm1a) was generated as part of the European Conditional Mouse 
Mutagenesis Program and Knockout Mouse Project (EUCOMM/KOMP) projects and 
Sanger Mouse Genetics Project 38.  Mice were generated from embryonic stem cell 
clone EPD0070_4_F09 and JM8.N4 ES cell line and maintained on a 
C57BL/6N;C57BL/6-Tyrc-Brd.  Genotyping was carried out as previously described 39. 
Animals were housed in specific pathogen-free conditions and placed on a Western 
high fat diet (Special Diet Services, Witham, UK) from 4 weeks of age with ad libitum 
access to autoclaved, nonacidified water and food and phenotyped according to a 
previously reported standard pipeline, including Dual-energy X-ray absorptiometry 
and high-resolution X-ray imaging 40. Bone lengths were derived from the original 
DICOM files of the left forearm and paw using Sante DICOM Editor 4 program 
(Santesoft, Athens, Greece).  All experiments were performed in accordance with the 
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UK Home Office regulations, UK Animals (Scientific Procedures) Act 1986. Adult 
phenotyping was performed blind to genotype groups, with a minimum of 7 animals 
per group. 
 
 
Prmt7tm1a/tm1a mouse data was analysed using RStudio running R version 3.1.2 and 
Phenstat package version 2.0.1.  This uses a mixed-model framework as described 41 
to assess the impact of genotype on phenotype.  The analysis was performed by 
loading mouse body weight into the starting model:  Y= Genotype+ Sex+ 
Genotype*Sex +Weight.   Multiple correction testing was performed on the global p-
value using the Hochberg correction.  
 
For mouse skeletal staining, mice were killed by lethal IP injection of anesthetic at 
P10 and confirmation of death was performed by cutting of the femoral artery. Skin 
and inner organs were removed and full skeletons were first fixed with 100% EtOH 
for 2 days and then placed in Alcian blue to stain proteoglycans for 24 hours. Then 
shortly washed with EtOH to remove rest of Alcian blue and cleared in 1%KOH for 24 
hours. Skeletons were then placed in Alizarin red staining solution, to detect calcium 
deposits for at 24 hours and then again in 1%KOH. Skeletons were then embedded in 
100% Glycerol, after ascending series of KOH-glycerol mixture (1%KOH:Gly v/v: 
80:20, 60:40, 40:60, 20:80). Pictures were acquired with a Leica stereomicroscope 
and Leica Application System (LAS V4) and bones were measured with Image J. For 
statistical analysis the Wilcoxon test was performed with R Studio (version 0.98.501) 
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Supplementary Information 
 
Supplementary Figure 1 Singleton ratio for last G in exon compared to LOF and 
missense variants  
Comparing the proportion of variants belonging to different functional classes that 
are singletons among the DDD parents. 
 
Supplementary Figure 2 Comparison of cumulative allele frequencies for loss-of-
function and functional variants in DDD versus ExAC. 
-log10 cumulative allele frequencies per gene obtained from unaffected DDD 
parents of European ancestry are on the X axis, and –log10 cumulative allele 
frequencies from the NFE subset of the ExAC dataset are on the Y axis. The dashed 
line identifies equivalence for DDD and ExAC derived cumulative allele frequencies. 
 
Supplementary Figure 3 Rates of autozygosity per gene within the probands 
The distribution of the proportion of probands autozygous across a given gene is 
shown. The grey vertical lines show the autozygosity proportions for the genes with 
P < 5 × 10-4, which fall in the bulk of distribution. The X-axis uses a logarithmic scale. 
 
Supplementary Figure 4 QQ plot from testing genes for enrichment of families with 
rare biallelic synonymous variants. 
Comparison of QQ plots from four different tests of genotype enrichment for rare, 
biallelicly inherited synonymous genotypes. Black dots show the QQ plot from 
testing for enrichment using cumulative allele frequencies from the NFE subset of 
ExAC (shaded black), without correcting for population structure or autozygosity. 
Red dots show the QQ plot after correcting for population structure within the DDD 
probands by considering all possible combinations of counts among the four 
ancestral continental populations defined in ExAC. Blue dots show a QQ plot after 
correcting for gene-specific autozygosity in the probands. Grey dots show a QQ plot 
after correcting for both population structure, and autozygosity, and is the closest 
match to the null expectation (shown as dashed red line). 
 
Supplementary Figure 5 QQ plot from testing similarity of Human-Phenotype-
Ontology terms among probands 
Comparison of QQ plots from testing similarity of HPO terms within a test dataset. 
The figure includes QQ plots from testing probands in genes with recurrent de novos 
(standard) and a distribution from testing the same genes, but with randomly 
sampled individuals (permuted). The permuted genes matched proband numbers to 
the number of recurrent de novos in each gene. The minimum p-value for these 
tests is limited to 1 x 10-5, which is determined by the number of iterations (100,000) 
used to test similarity of HPO terms. 
 
Supplementary Figure 6 Protein modeling of missense variants in PRMT7  
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a. The overall structure of the human PRMT7 model based on mouse Prmt7 (PDB ID: 
4C4A). The protein contains two catalytic modules (shown by horizontal line) each 
containing an AdoMet-binding domain (orange), C-terminal β-barrel (red) and a 
dimerisation domain(blue). Residues that are mutated in DDD patients are shown in 
magenta. The donor homolog S-adenosyl homocysteine (SAH) was bound to the 
mouse structure and is also shown here too.b. The predicted consequences of the 
missense mutations detected in this study on PRMT7 protein structure and function. 
Arg32Thr: Residue arginine 32 sits at the entrance of the N-terminal catalytic module 
(orange and red) but mainly interacts with residues from the C-terminal catalytic 
module (blue, raspberry and olive). R32T mutation results in the loss of a hydrogen 
bond and changes the nature of the donor-binding pocket. Arg387Gly: E478Q 
mutated proteins have less than 0.1% activity of the native protein 
[PMID:25195753]. This is attributed to the loss of critical H-bonds this residue makes 
with R387 and R378. Mutation R387G will result in the loss of these H-bonds this 
likely effects activity of the protein. Trp494Arg: W494 sits on anα-helix that forms 
part of the predicted donor-binding site of the C-terminal catalytic module 
surrounded by hydrophobic residues. The W494R mutation is predicted to cause 
conformational change around this region and lead to changes in the donor-binding 
pocket. 
  
Supplementary Figure 7 Skeletal phenotyping of 10-day old PRMT7 loss-of-function 
mice: reduced body size, bone defects and reduced digit length. 
Prmt7tm1a/tm1a mice have severely reduced body size (A,B,H) and weight (G) 
compared to control littermates. Prmt7tm1a/wt mice are not affected and resemble wt 
littermates (data not shown). Skeletal staining of Prmt7wt/wt and Prmt7tm1a/tm1a was 
examined at P10 for full skeleton (B), hind paws (C), forelimbs (D), skull (E), and rib 
cage (F). Mice display growth retardation (B-F), and brachydactyly of the 5th 
metatarsal bone (C,I). The null mice present a duplication of the first rib (F, 100% of  
Prmt7tm1a/tm1a mice at P10, N=5).  Although all digit lengths were reduced in the 
mutant mice, when normalised to overall body size reduction (using radius length as 
proxy), only the 5th metatarsal shows statistically significant disproportional 
reduction in length compared to controls (I).  Metacarpal bones normalized to radius 
were not significantly reduced in Prmt7tm1a/tm1a mice at this stage (P10, data not 
shown). Scale bars in B-F indicate 5mm. 
 
 
Supplementary Movie. Ciliary motility in Mmp21 Miri mutant 
Videomicroscopy of the embryonic node from an Mmp21 Miri mutant shows robust 
ciliary motility and  leftward fluid flow similar to that seen in the embryonic node of 
a wild-type littermate control.  Flow videos are shown at 200% real time to facilitate 
visualization of bead movement, while cilia motion videos are shown at 15% real 
time to allow better visualization of nodal ciliary motion. 
 
Supplementary Table 1. Additional families with previously implicated autosomal 
recessive genes.  
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Numbers of families supporting previously weakly implicated autosomal recessive 
genes. The presumed causative variants in these genes are available in the DECIPHER 
reported variants track. 
 
Supplementary Table 2. Genotype and phenotype matching p values for all 74 
recurrently observed candidate recessive genes 
 
 
Supplementary Table 3. Clinical data for four novel recessive genes  
  
Supplementary Table 4. Statistical analysis of Prmt7 mouse model 
A summary of the statistical data from the Prmt7tm1a/tm1a mouse.  The raw data was 
analysed using a mixed-model framework incorporating body weight as a covariant 
in the starting equation.  For each parameter, the data presented as mean±SD 
(columns 2, 3, 5, 6), the effect size of the change for that sex derived from the 
mixed-model framework (columns 4 and 7), the global p-value for genotype 
contribution (column 8), the adjusted global p-value for genotype contribution using 
the Hochberg correction for multiple testing (column 9), the p-value for sexual 
dimorphism (column 10) and a classification of whether the phenotype is applicable 
to either or both sexes (column 11).   For DEXA parameters, n= 37 Female WTs, 7 
Female Prmt7tm1a/tm1a, 45 Male WTs and 8 Male Prmt7tm1a/tm1a.  For X-Ray analysis, 
n= 36 Female WTs, 7 Female Prmt7tm1a/tm1a, 41 Male WTs and 8 Male Prmt7tm1a/tm1a.  
An adjusted global p-value for genotype contribution value less than 0.05 is 
considered significant for genotype effect on phenotype. 
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